BPC-157 and TB-500 for pain and energy: what TikTok gets wrong

What's this video probably claiming?

Based on the caption and hashtags, this creator is pitching a peptide guide aimed at chiropractic clinics, framing compounds like BPC-157 and TB-500 as versatile tools for pain relief, fat loss, energy, and sexual health. The hashtags name BPC-157 and TB-500 explicitly, two of the most hyped compounds in the compounded peptide space right now. The framing of peptides as something that can "completely change the game" across four unrelated health categories is a classic overpromise structure. The guide appears to be a lead-generation asset, meaning the actual claims are probably more aggressive in the downloadable material than in the video itself. Chiropractic clinics are increasingly being targeted by peptide marketers as distribution points, which raises immediate questions about scope of practice, compounding pharmacy relationships, and whether the claims being made to practitioners hold up to any serious scrutiny.

What does the science actually show?

BPC-157 has genuine preclinical support. Animal studies, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design and Journal of Physiology-Paris, show anti-inflammatory and tissue-repair effects at doses around 10 mcg/kg in rodent models. TB-500, a synthetic fragment of thymosin beta-4, has shown some wound-healing and angiogenic activity in animal models. The problem is the translation gap. There are no completed Phase III human clinical trials for either compound as of mid-2025. A 2023 paper in Frontiers in Pharmacology noted that while BPC-157 shows consistent effects in animal ulcer and tendon models, human pharmacokinetic data remains sparse. For fat loss specifically, peptides like CJC-1295 and ipamorelin stimulate growth hormone release, but a 2006 Sigalos and Pastuszak review in Sexual Medicine Reviews noted that GH secretagogues in healthy adults produce modest IGF-1 increases, not dramatic body composition changes on their own.

Where does the social media noise diverge from clinical reality?

The "four category" framing, pain, energy, fat loss, sexual health, is where things get genuinely misleading. No single peptide or peptide stack has been validated in human RCTs for all four outcomes simultaneously. Creators bundle these claims because each individual compound has at least one plausible mechanism, BPC-157 for gut and tendon healing, TB-500 for tissue repair, GHRPs for GH release, and the audience assumes those mechanisms stack into a comprehensive solution. They do not, at least not in any controlled human data. The FDA has also taken direct action here: BPC-157 and TB-500 were removed from the bulk substances list for compounding in 2023, meaning compounded versions face significant regulatory uncertainty in the US. Marketing these to chiropractic clinics without disclosing that regulatory context is a material omission. Energy and libido claims for peptides like PT-141 and Semax rely almost entirely on anecdotal reports and small open-label studies.

What should you actually know?

If you are a patient or a practitioner watching content like this, the right question is not whether peptides "work" in general but whether there is human evidence for a specific compound at a specific dose for a specific outcome in a population that resembles you. Right now, that evidence is thin for most of the compounds being marketed. BPC-157 has the deepest preclinical record but zero approved human indications. TB-500 is similarly supported only in animal and in vitro work. The regulatory status of compounded peptides in the US changed meaningfully in 2023 and 2024, and any guide being sold to clinics that does not address that is already outdated or deliberately vague. Legitimate telehealth platforms order labs, take medical histories, and do not frame a single category of compounds as solving four unrelated health problems. If a guide for chiropractic clinics is making those claims, that is a marketing document, not a clinical one.